The Gold Trade, May 24
Health Care: Drugs
KaloBios Pharmaceuticals Inc (KBIO: NASDAQ)
$5.85 0.16 | 2.81%
05/24/13 - 04:00 PM ET
7.73K / 57.90K
Vol / Avg. Vol:5.61 / 5.69
Open / Prev. Close:5.50 - 5.98
Today's Range:5.50 - 8.25
52 Wk Range:0.00%
Performance YTD:TheStreet Rating:
Portfolios with KBIO
- Portfolio NameUser Type
Latest KBIO Headlines from TheStreet
- Top Insider Trades: EA KBIO VRTU BDBD 02.05.13 | 09:02 am
- Small IPOs Bring Risks
01.28.13 | 12:01 pm
Press Releases for KBIO
- KaloBios To Present At Credit Suisse Antibody Conference - PR Newswire 05.08.13 | 04:05 pm
- KaloBios To Present At Needham Healthcare Conference - PR Newswire 04.24.13 | 04:04 pm
- U.S. FDA Grants Fast-Track Designation To Sanofi Pasteur And KaloBios' Novel Biologic Candidate For Pseudomonas Aeruginosa - PR Newswire 04.23.13 | 08:04 am
- KaloBios' Targeted Antibacterial KB001-A To Be Featured In BIO 2013 Panel Discussion Of "New Defenses Against Old Enemies" - PR Newswire 04.17.13 | 04:04 pm
- KaloBios To Present At Future Leaders In The Biotech Industry Conference - PR Newswire 04.01.13 | 04:04 pm
- Bioassociate Announces Initiation Of Coverage On KaloBios Pharmaceuticals, Inc. - PR Newswire 02.27.13 | 09:02 am
- KaloBios Presents Clinical Results With Anti-GM-CSF Antibody In Persistent Asthma Data From KB002 Phase 1/2 Study Presented At The American Academy Of Allergy, Asthma And Immunology Meeting - PR Newswire 02.26.13 | 04:02 pm
- KaloBios Pharmaceuticals Completes Initial Public Offering - PR Newswire 02.07.13 | 08:02 am
Partner Headlines for KBIO
